Revolutionary Tumor-Agnostic + Informed Blood Test
Datar Cancer Genetics (DCG) announced the launch of Target-MRD, an advanced molecular residual disease (MRD) monitoring blood test for solid organ cancers. Target-MRD is a blood test based on tumor-agnostic next-generation sequencing (NGS) and customized, tumor-informed droplet digital PCR (dd-PCR) assay. In patients who undergo initial anticancer treatments, a small number of tumor cells can survive and persist in the body. This low ‚disease burden‘ is capable of leading to a relapse, which can remain undetectable by traditional genomic and imaging methods. Timely detection of this ‚minimal residual disease‘ is now considered critical towards mitigating risks of recurrence. Target-MRD offers personalized, ultra-sensitive detection and monitoring of residual disease at the molecular level, if any, to assist oncologists to intervene early, well before the disease gets out of hand. Target-MRD combines tumor-agnostic (to detect tumor evolution) and tumor-informed (specific to a…
